Trauma Injury clinical trials at UC Davis
2 in progress, 1 open to eligible people
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
open to eligible people ages up to 17 years
The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.
Sacramento, California and other locations
Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study
Sorry, not yet accepting patients
Trauma is the leading cause of death and disability in children in the United States. The objective of this study is to evaluate the benefits and harms of tranexamic acid (TXA; a drug that stops bleeding) in severely injured children with hemorrhagic brain and/or torso injuries. Using thromboelastography, we will measure baseline fibrinolysis to assess for treatment effects of TXA at different levels of fibrinolysis.
Our lead scientists for Trauma Injury research studies include Nathan Kuppermann, MD, MPH Daniel Nishijima, MD.
Last updated: